PMID- 30020021 OWN - NLM STAT- MEDLINE DCOM- 20181231 LR - 20181231 IS - 1477-0962 (Electronic) IS - 0961-2033 (Linking) VI - 27 IP - 11 DP - 2018 Oct TI - Composite urinary biomarkers to predict pathological tubulointerstitial lesions in lupus nephritis. PG - 1778-1789 LID - 10.1177/0961203318788167 [doi] AB - Objective This study aimed to evaluate the clinical value of urinary biomarkers including kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), and monocyte chemoattractant protein-1 (MCP-1) in lupus nephritis. Methods A total of 109 biopsy-proven lupus nephritis patients were included and 50 healthy individuals were used as normal controls. Urinary KIM-1, NGAL, and MCP-1 levels were measured by ELISA and their correlations with clinical and histological features were assessed. Receiver operating characteristic curves were performed and the Cox regression model was applied to identify prognostic factors associated with renal outcomes. Results Active lupus nephritis patients exhibited elevated urinary levels of KIM-1, NGAL, and MCP-1 compared with lupus nephritis patients in remission ( P < 0.001) and normal controls ( P < 0.001). The urinary KIM-1 level was correlated with pathological tubular atrophy ( r = 0.208, P < 0.05) and increased significantly in the presence of interstitial inflammatory lesions ( P = 0.031). Urinary KIM-1, NGAL, and MCP-1 levels were higher in patients with active tubulointerstitial lesions than in those with only chronic lesions ( P = 0.015, P = 0.230, and P = 0.086, respectively). A combination of KIM-1, NGAL, and MCP-1 was a good indicator for diagnosing active tubulointerstitial lesions (area under the curve: 0.796). The combination of KIM-1 and NGAL was identified as an independent risk factor for renal outcomes (hazard ratio = 7.491, P < 0.05). Conclusion Urinary KIM-1, NGAL, and MCP-1 levels were associated with kidney injury indices in lupus nephritis. The combination of the three biomarkers showed increased power in predicting tubulointerstitial lesions and renal outcomes. FAU - Ding, Y AU - Ding Y AD - 1 Renal Division, Department of Medicine, Peking University First Hospital, Beijing, PR China. AD - 2 Department of Nephrology, Peking University International Hospital, Beijing, PR China. FAU - Nie, L-M AU - Nie LM AD - 1 Renal Division, Department of Medicine, Peking University First Hospital, Beijing, PR China. AD - 3 Renal Division, Department of Medicine, First Hospital of Shijiazhuang, Shijiazhuang, Hebei, PR, China. FAU - Pang, Y AU - Pang Y AD - 1 Renal Division, Department of Medicine, Peking University First Hospital, Beijing, PR China. AD - 4 Institute of Nephrology, Peking University, Beijing, PR China. AD - 5 Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, PR China. AD - 6 Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, PR China. FAU - Wu, W-J AU - Wu WJ AD - 1 Renal Division, Department of Medicine, Peking University First Hospital, Beijing, PR China. AD - 4 Institute of Nephrology, Peking University, Beijing, PR China. AD - 5 Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, PR China. AD - 6 Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, PR China. AD - 7 Peking-Tsinghua Center for Life Sciences; Beijing, PR China. FAU - Tan, Y AU - Tan Y AD - 1 Renal Division, Department of Medicine, Peking University First Hospital, Beijing, PR China. AD - 4 Institute of Nephrology, Peking University, Beijing, PR China. AD - 5 Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, PR China. AD - 6 Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, PR China. FAU - Yu, F AU - Yu F AD - 1 Renal Division, Department of Medicine, Peking University First Hospital, Beijing, PR China. AD - 2 Department of Nephrology, Peking University International Hospital, Beijing, PR China. AD - 4 Institute of Nephrology, Peking University, Beijing, PR China. AD - 5 Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, PR China. AD - 6 Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, PR China. FAU - Zhao, M-H AU - Zhao MH AD - 1 Renal Division, Department of Medicine, Peking University First Hospital, Beijing, PR China. AD - 4 Institute of Nephrology, Peking University, Beijing, PR China. AD - 5 Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, PR China. AD - 6 Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, PR China. AD - 7 Peking-Tsinghua Center for Life Sciences; Beijing, PR China. LA - eng PT - Journal Article DEP - 20180718 PL - England TA - Lupus JT - Lupus JID - 9204265 RN - 0 (Biomarkers) RN - 0 (CCL2 protein, human) RN - 0 (Chemokine CCL2) RN - 0 (HAVCR1 protein, human) RN - 0 (Hepatitis A Virus Cellular Receptor 1) RN - 0 (LCN2 protein, human) RN - 0 (Lipocalin-2) SB - IM MH - Adult MH - Beijing MH - Biomarkers/*urine MH - Case-Control Studies MH - Chemokine CCL2/urine MH - Female MH - Hepatitis A Virus Cellular Receptor 1/analysis MH - Humans MH - Kidney Tubules/*pathology MH - Lipocalin-2/urine MH - Lupus Nephritis/pathology/*urine MH - Male MH - Proportional Hazards Models MH - ROC Curve MH - Young Adult OTO - NOTNLM OT - Renal lupus OT - systemic lupus erythematosus OT - tubulointerstitial lesions OT - vasculitis EDAT- 2018/07/19 06:00 MHDA- 2019/01/01 06:00 CRDT- 2018/07/19 06:00 PHST- 2018/07/19 06:00 [pubmed] PHST- 2019/01/01 06:00 [medline] PHST- 2018/07/19 06:00 [entrez] AID - 10.1177/0961203318788167 [doi] PST - ppublish SO - Lupus. 2018 Oct;27(11):1778-1789. doi: 10.1177/0961203318788167. Epub 2018 Jul 18.